Opthea

Opthea Limited is an Australian biotechnology company dedicated to developing innovative biologic therapies for eye diseases. Its primary focus is on OPT-302, a novel compound designed to inhibit vascular endothelial growth factors VEGF-C and VEGF-D, which are responsible for abnormal blood vessel growth and leakage. These conditions are often associated with serious eye diseases, particularly wet age-related macular degeneration (wet AMD). The company's research is grounded in a robust intellectual property portfolio that encompasses various targets related to vascular and lymphatic vessel growth and related complications. Opthea aims to advance the treatment landscape for patients suffering from debilitating eye conditions through its pioneering therapeutic approaches.